Bladder Cancer: Over a Decade Cancer-Free with Anktiva, T-Cells & Immune Memory

Addressing Immune System Collapse

• 💡 The core principle behind this treatment is that immune system collapse is the root cause of early mortality from both cancer and infection.
• 🎯 The initial focus of this innovative approach was specifically on non-muscle invasive bladder cancer (NMIBC).

The Anktiva (N-803) + BCG Clinical Trial

• 🚀 A clinical trial for the Anktiva (N-803) plus BCG combination therapy commenced in 2014, involving patients who were initially BCG naive.
• ✅ The trial demonstrated no dose-limiting toxicity, indicating the treatment was well-tolerated by participants.
• 💬 Patient testimonials, including one from Alvera who had a history of multiple cancers, highlighted the positive experience and hope derived from participating.

Mechanism of Immune Enhancement

• 🔬 The N-803 therapy significantly increases the proliferation of T-cells, NK cells, and memory T-cells within the body.
• 🧠 A key discovery was the importance of memory T-cells in achieving a long duration of complete remission.

Unprecedented Durability and Patient Outcomes

• ✨ The therapy has shown remarkable durability, with many participants remaining cancer-free for nearly a decade.
• 👏 Patients reported feeling "not scared anymore" and enjoying life, signifying a profound improvement in their quality of life.
• 📈 A urologist with over 20 years of practice attested to the unprecedented durability observed in this clinical trial's results, offering a